{
    "name": "latanoprost/netarsudil ophthalmic",
    "comment": "Rx",
    "other_names": [
        "Rocklatan"
    ],
    "classes": [
        "Antiglaucoma",
        "Combos"
    ],
    "source": "https://reference.medscape.com/drug/rocklatan-latanoprost-netarsudil-ophthalmic-1000220",
    "pregnancy": {
        "common": [
            "There are no available data regarding ophthalmic use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Reproduction studies of latanoprost showed embryofetal lethality in rabbits; no embryofetal lethality was observed at a dose ~15 times higher than the recommended human ophthalmic dose (RHOD); in 4 of 16 pregnant rabbits, no viable fetuses were present at a dose ~80 times RHOD",
                    "IV administration of netarsudil to pregnant rats and rabbits during organogenesis did not produce adverse embryofetal effects at clinically relevant systemic exposures"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available regarding the presence of netarsudil or latanoprost in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Systemic exposure to netarsudil following topical ocular administration is low, and it is not known whether measurable levels of netarsudil would be present in maternal milk following topical ocular administration",
            "Consider the development and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Latanoprost reported to cause changes to pigmented tissues (owing to increased melanin content in melanocytes), including increased pigmentation of the iris, periorbital tissue, and eyelashes; pigmentation is expected to increase as long as latanoprost is administered; inform patients of possibility of increased pigmentation",
                "Latanoprost may gradually change eyelashes and vellus hair in the treated eye; changes include increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth of eyelashes; eyelash changes are usually reversible when treatment discontinued",
                "Caution with history of intraocular inflammation (iritis/uveitis); should generally not be used with active intraocular inflammation because latanoprost may exacerbate inflammation",
                "Macular edema, including cystoid macular edema, reported with latanoprost; caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or those with known risk factors for macular edema",
                "Reactivation of herpes simplex keratitis reported with latanoprost; caution with history of herpetic keratitis; avoid with active herpes simplex keratitis as administration may exacerbate inflammation",
                "Risk of bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products",
                "Remove contact lenses before administration"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "In vitro studies show precipitation of latanoprost solution occurs when mixed with thimerosal-containing ophthalmic drops",
                        "Combining 2 or more prostaglandins or prostaglandin analogues is not recommended; administration of prostaglandin drug products more than once daily may mitigate the IOP-lowering effect or cause paradoxical elevations in IOP"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "bimatoprost",
            "description": {
                "common": "latanoprost, bimatoprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "latanoprostene bunod ophthalmic",
            "description": {
                "common": "latanoprost, latanoprostene bunod ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tafluprost",
            "description": {
                "common": "latanoprost, tafluprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "travoprost ophthalmic",
            "description": {
                "common": "latanoprost, travoprost ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "latanoprost, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "latanoprost, aspirin rectal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromfenac ophthalmic",
            "description": {
                "common": "latanoprost, bromfenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "latanoprost, celecoxib. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "latanoprost, choline magnesium trisalicylate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "latanoprost, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac ophthalmic",
            "description": {
                "common": "latanoprost, diclofenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "latanoprost, diflunisal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "latanoprost, etodolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "latanoprost, fenoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "latanoprost, flurbiprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen ophthalmic",
            "description": {
                "common": "latanoprost, flurbiprofen ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "latanoprost, ibuprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "latanoprost, ibuprofen IV. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen/famotidine",
            "description": {
                "common": "latanoprost, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "latanoprost, indomethacin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "latanoprost, ketoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "latanoprost, ketorolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "latanoprost, ketorolac intranasal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac ophthalmic",
            "description": {
                "common": "latanoprost, ketorolac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "latanoprost, meclofenamate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "latanoprost, mefenamic acid. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "latanoprost, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "latanoprost, nabumetone. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "latanoprost, naproxen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nepafenac ophthalmic",
            "description": {
                "common": "latanoprost, nepafenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "latanoprost, oxaprozin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "latanoprost, piroxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "latanoprost, salsalate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "latanoprost, sulindac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "latanoprost, tolmetin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Conjunctival hyperemia",
            "percent": "59"
        },
        {
            "name": "Instillation site pain",
            "percent": "20"
        },
        {
            "name": "Corneal verticillata",
            "percent": "15"
        },
        {
            "name": "Conjunctival hemorrhage",
            "percent": "11"
        },
        {
            "name": "Eye pruritus",
            "percent": "5-8"
        },
        {
            "name": "Reduced visual acuity",
            "percent": "5-8"
        },
        {
            "name": "Increased lacrimation",
            "percent": "5-8"
        },
        {
            "name": "Instillation site discomfort",
            "percent": "5-8"
        },
        {
            "name": "Blurred vision",
            "percent": "5-8"
        },
        {
            "name": "Instillation site erythema",
            "percent": null
        },
        {
            "name": "Corneal staining",
            "percent": null
        },
        {
            "name": "Increased lacrimation",
            "percent": null
        },
        {
            "name": "Eyelid erythema",
            "percent": null
        },
        {
            "name": "Foreign body sensation",
            "percent": null
        },
        {
            "name": "Punctate keratitis",
            "percent": null
        },
        {
            "name": "Burning and stinging",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Increased iris pigmentation",
            "percent": null
        },
        {
            "name": "Excessive tearing",
            "percent": null
        },
        {
            "name": "Eyelid discomfort",
            "percent": null
        },
        {
            "name": "Dry eye",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Eyelid margin crusting",
            "percent": null
        },
        {
            "name": "Eyelid erythema",
            "percent": null
        },
        {
            "name": "edema",
            "percent": null
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": null
        },
        {
            "name": "nasopharyngitis",
            "percent": null
        },
        {
            "name": "influenza",
            "percent": null
        },
        {
            "name": "Photophobia",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "arthralgia",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "allergic reactions",
            "percent": null
        }
    ]
}